Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Williams Companies    WMB


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Pipeline Operator Williams Comes Under Fire -- Update

share with twitter share with LinkedIn share with facebook
04/07/2020 | 04:31pm EDT

By Corrie Driebusch and Rebecca Elliott

An influential proxy adviser has taken the unusual step of urging shareholders to withhold votes for the chairman of Williams Cos. after the pipeline operator adopted a poison pill to fend off unwanted suitors.

Institutional Shareholder Services Inc., or ISS, recommends against supporting Williams Chairman Stephen Bergstrom in director elections at the company's annual meeting April 28, according to a client note from the proxy adviser that was viewed by The Wall Street Journal. The report cites the "highly restrictive" nature of the pill, which kicks in if an unwanted shareholder buys a stake of just 5%.

Williams, whose pipelines transport oil and natural gas, on March 19 joined a swell of more than 20 companies adopting poison pills as their shares plunge amid the coronavirus pandemic.

Poison pills are antitakeover measures that can also be used to neutralize shareholder activists. When an outsider buys up more than a certain amount of the stock of a company with one, new shares flood the market and make it more expensive to acquire a controlling stake. Many investors frown on poison pills because they can insulate companies from sometimes-beneficial outside forces and suitors who might offer a significant takeover premium.

The threshold for the Williams pill, which will remain in effect until next March, is exceptionally low compared with others. According to ISS, of the 14 companies that adopted poison pills between March 13 and March 30, all of the others chose triggers ranging from 10% to 20%. It calls the threshold for the Williams pill "extremely rare."

The proxy firm adds that it recognizes this is a "unique time" and it doesn't take a broad stand against implementing poison pills in this environment. ISS recommends a "cautionary" vote for all other Williams directors, including Chief Executive Alan Armstrong.

A Williams spokeswoman called the ISS recommendation "perplexing," saying in a written statement that the company's board acted in the best interest of shareholders and that the 5% trigger level isn't "highly restrictive." She added that Williams reached out to major shareholders after adopting the pill and none of them indicated that they would vote against any board members in the coming election.

The Tulsa, Okla., company has said it adopted the pill in response to its share-price decline, not because of a specific threat.

Williams' stock fell more than 25% in March and was down more than 40% since the start of the year as of Monday's close, battered by the pandemic as well as a sharp decline in energy prices. The company's market capitalization was about $16 billion as of Monday.

Glass Lewis & Co., another major proxy adviser, has said it doesn't believe shareholders ought to withhold votes from any board members over the pill at this time.

Mr. Bergstrom is running unopposed on the director slate, so there is little to no chance of his removal. Last year, nearly 99% of investors voted for him, according to the ISS report. However, ISS carries a lot of clout with big institutional shareholders and a significant vote against the chairman would send a message to the company as well as any others considering a similar move.

Sabastian Niles, a partner at law firm Wachtell, Lipton, Rosen & Katz who advises corporate clients on activism and takeover defense, said he tells companies that their pills should be designed with circumstances that are specific to them in mind.

"ISS and institutional investors are not writing a blank check and companies should not reflexively rush to adopt a pill prematurely and without good reason," he said.

ISS criticizes Williams for what it says is a failure to consider alternatives, such as a shorter-term pill or one with a higher trigger level, and for not using its annual meeting to seek shareholder ratification of the plan.

Write to Corrie Driebusch at corrie.driebusch@wsj.com and Rebecca Elliott at rebecca.elliott@wsj.com


Stocks mentioned in the article
ChangeLast1st jan.
BEST INC. 3.42% 4.53 Delayed Quote.-21.22%
ISS A/S -0.61% 106.35 Delayed Quote.-33.06%
LONDON BRENT OIL 2.80% 42.91 Delayed Quote.-36.97%
MEMBERS CO., LTD. -4.13% 1394 End-of-day quote.-38.78%
SEEK LIMITED 0.87% 21.99 End-of-day quote.-2.48%
THE NEW HOME COMPANY INC. 0.63% 3.2 Delayed Quote.-31.76%
WILLIAMS COMPANIES 1.44% 19.08 Delayed Quote.-20.70%
share with twitter share with LinkedIn share with facebook
06/28Chesapeake Energy's bankruptcy delivers hit to reeling pipeline, service firm..
06/17WILLIAMS : Announces Deepwater Tieback Agreement at Devils Tower
06/11WILLIAMS COMPANIES : Ex-dividend day for
06/10WILLIAMS : CEO to Present at J.P. Morgan 2020 Energy, Power & Renewables Confere..
05/28WILLIAMS : Announces Plans to Develop Solar Power at Key Facilities
05/14WILLIAMS COMPANIES, INC. : Entry into a Material Definitive Agreement, Financial..
05/14WILLIAMS COMPANIES, INC. : Regulation FD Disclosure, Other Events, Financial Sta..
05/12WILLIAMS : Prices $1 Billion of Senior Notes
05/08WILLIAMS COMPANIES, INC. : Entry into a Material Definitive Agreement, Creation ..
05/07Williams Up; In Gas Transportation Services Agreement with Chevron, Total
More news
Financials (USD)
Sales 2020 7 422 M - -
Net income 2020 524 M - -
Net Debt 2020 22 079 M - -
P/E ratio 2020 44,6x
Yield 2020 8,34%
Capitalization 23 148 M 23 148 M -
EV / Sales 2019
EV / Sales 2020 6,09x
Nbr of Employees 4 812
Free-Float 96,9%
Duration : Period :
Williams Companies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WILLIAMS COMPANIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 26
Average target price 22,84 $
Last Close Price 19,08 $
Spread / Highest target 36,3%
Spread / Average Target 19,7%
Spread / Lowest Target 4,82%
EPS Revisions
Alan S. Armstrong President, Chief Executive Officer & Director
Stephen W. Bergstrom Chairman
Michael G. Dunn Chief Operating Officer & Executive Vice President
John D. Chandler Chief Financial Officer & Senior Vice President
Murray D. Smith Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ENBRIDGE INC.-20.05%61 577
KINDER MORGAN, INC.-29.57%33 719
MPLX LP-31.93%18 346